Introduced
Committee
Markup
Reported
Floor
Passed
Enacted
HR.4139 119th Congress

Cutting Copays Act

Status
In Committee
Sponsor
McGarvey, Morgan (D-Kentucky)
Official Source
Investability
0/100
Stage
COMMITTEE
Related Bills
0
Full Text
2,127 chars
Alive
Yes
GovGreed Synthesis ·
Cutting Copays Act This bill eliminates cost-sharing for generic drugs for those with the lowest-income under the Medicare prescription drug benefit's Low-Income Subsidy Program beginning in 2026.
119 HR 4139 IH: Cutting Copays Act U.S. House of Representatives 2025-06-25 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 119th CONGRESS 1st Session H. R. 4139 IN THE HOUSE OF REPRESENTATIVES June 25, 2025 Mr. McGarvey (for himself and Mr. Bilirakis ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to provide for adjustments to the Medicare part D cost-sharing reductions for low-income individuals. 1. Short title This Act may be cited as the Cutting Copays Act . 2. Adjustments to Medicare part D cost-sharing reductions for low-income individuals Section 1860D–14(a) of the Social Security Act ( 42 U.S.C. 1395w–114(a) ) is amended in paragraph (1)(D)(ii)— (1) by striking that does not exceed $1 for and all that follows through the period at the end and inserting that does not exceed— (I) for plan years before plan year 2026— (aa) for a generic drug or a preferred drug that is a multiple source drug (as defined in section 1927(k)(7)(A)(i)), $1 or, if less, the copayment amount applicable to an individual under clause (iii); and (bb) for any other drug, $3 or, if less, the copayment amount applicable to an individual under clause (iii); and ; and (2) by adding at the end the following new subclauses: (II) for plan year 2026— (aa) for a generic drug, $0; and (bb) for any other drug, the dollar amount applied under this clause (after application of paragraph (4)(A)) for plan year 2023 for a drug described in subclause (I)(bb); and (III) for a subsequent year, the dollar amount applied under this clause for the previous year for the drug, increased by the annual percentage increase in the consumer price index (all items; U.S. city average) as of September of such previous year. .
🔒 GovGreed Pro · Trading Intelligence on HR.4139 Get Access — $24.50/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated recently.
Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records.
GovGreed is not affiliated with the U.S. Government. Not financial advice.